Key Takeaways Amneal Pharmaceuticals gains GLP-1 exposure via a Pfizer-linked manufacturing partnership.AMRX avoids clinical risks, focusing on execution, supply and manufacturing scale.AMRX leverages peptide and injectable capacity to expand into higher-value products.Amneal Pharmaceuticals (AMRX) has been steadily building a growth model that extends beyond traditional oral solid generics. That model increasingly leans on complex injectables, biosimilars, and specialized manufacturing capabilities that ca ...